Amicus Therapeutics, Inc. (FOLD) Stock
Amicus Therapeutics, Inc.
Company profile
Amicus Therapeutics reported revenue of $634.21 million for fiscal year 2025, up 20.0% from fiscal year 2024. Ex-U.S. was its largest region in fiscal year 2025, with 58% of revenue. Our analysis of its filings shows revenue growing from $399.36 million in fiscal year 2023 to $634.21 million in fiscal year 2025, 26.0% a year on average.
What stands out
- It reported a net loss in each of its last 5 fiscal years; the loss narrowed from $56.11 million in fiscal year 2024 to $27.11 million in fiscal year 2025.
- It spent $135.84 million on research and development in fiscal year 2025, 21.4% of its revenue.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
Largest shareholders
- Vanguard Fiduciary Trust Co.9.57%
- Wellington Trust Co., NA9.48%
- BlackRock Advisors LLC8.29%
- Avoro Capital Advisor LLC5.86%
- William Blair Investment Management LLC4.77%
Share of the company, as of November 8, 2025
In the news
- Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacksNew York Post ·
- Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights
- OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—EKSO, FOLD, CWAN, and JHG
How much revenue does Amicus Therapeutics make?
Amicus Therapeutics reported $634.21 million in revenue for fiscal year 2025, up 20.0% from $528.30 million in fiscal year 2024.
Where does Amicus Therapeutics make most of its revenue?
Ex-U.S.: 58% of revenue by region in fiscal year 2025, followed by United States (42%).
What companies are similar to Amicus Therapeutics?
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include BioMarin Pharmaceutical Inc. (BMRN), Disc Medicine, Inc. (IRON), NewAmsterdam Pharma Company N.v. (NAMS), Maze Therapeutics, Inc. (MAZE).
Has Amicus Therapeutics made a profit in recent years?
Net income by fiscal year: FY2021, a loss of $250.46 million; FY2022, a loss of $236.57 million; FY2023, a loss of $151.58 million; FY2024, a loss of $56.11 million; FY2025, a loss of $27.11 million. It reported a net loss in each of these 5 years.
How has Amicus Therapeutics' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, $305.51 million; FY2022, $329.23 million; FY2023, $399.36 million; FY2024, $528.30 million; FY2025, $634.21 million.
Data as of .
How to cite: DataPorium, “Amicus Therapeutics, Inc. (FOLD)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/FOLD